X0206 3 2021-01-28 0 0001454789 CATABASIS PHARMACEUTICALS INC CATB 0001730615 Violin Jonathan C/O CATABASIS PHARMACEUTICALS, INC. 100 HIGH STREET, FLOOR 28 BOSTON MA 02110 1 0 0 0 Common Stock 543373 I By Lazarus Life Sciences I, LLC Warrant (Right to Buy) 0.35 2030-12-14 Common Stock 185136 I By Viridian, LLC Warrant (Right to Buy) 341.70 2030-12-14 Series X Convertible Preferred 2805 I By Viridian, LLC Series X Convertible Preferred Stock Common Stock 8234 I By Lazarus Life Sciences I, LLC On January 28, 2021, Issuer completed its merger with Quellis Biosciences, Inc. (the "Merger") in accordance with the terms of the Agreement and Plan of Merger, dated January 28, 2021. In connection with the Merger, (i) a limited liability company in which the Reporting Person has an indirect interest received shares of Issuer common stock and shares of Series X Convertible Preferred Stock in exchange for 350,000 shares of Quellis Biosciences, Inc. common stock and (ii) a limited liability company in which the Reporting Person holds a profits interest received warrants to purchase shares of Issuer common stock and shares of Series X Convertible Preferred Stock in exchange for a warrant to purchase 119,251 shares of Quellis Biosciences, Inc. common stock. The Reporting Person disclaims beneficial ownership of the securities held by both limited liability companies, except to the extent of his pecuniary interest therein. The warrant is exercisable as to 52.1% of the shares subject thereto as of January 21, 2021 and the remaining shares become exercisable at a rate of 2.0833% each month thereafter until fully exercisable on December 21, 2022, subject to continued services by a specified advisor to Issuer through each vesting date. Upon stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of common stock, each share of Series X Non-Voting Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations. Exhibit 24 - Power of Attorney. /s/ Benjamin Harshbarger, attorney-in-fact for Jonathan Violin 2021-02-01